A gene therapy for Huntington's disease is facing a new regulatory hurdle. There is uncertainty over which specific gene therapy is affected, with some outlets mentioning uniQure's AMT-130, and the impact on the company's stock has been inconsistent. The FDA's stance on individualized medicines and AAV gene therapy is also being questioned, amid criticism of the agency's decisions on rare disease drugs.